186 related articles for article (PubMed ID: 37401939)
21. Characteristics and significance of programmed cell death-related gene expression signature in skin cutaneous melanoma.
Wu X; Chen S; Ji Q; Chen H; Chen X
Skin Res Technol; 2024 May; 30(5):e13739. PubMed ID: 38766879
[TBL] [Abstract][Full Text] [Related]
22. LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.
Wang Y; Gong H; Cao Y
Hereditas; 2023 May; 160(1):26. PubMed ID: 37248547
[TBL] [Abstract][Full Text] [Related]
23. The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.
Lv Y; Yuan CH; Han LY; Huang GR; Ju LC; Chen LH; Han HY; Zhang C; Zeng LH
Dis Markers; 2022; 2022():4091978. PubMed ID: 35607442
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma.
Lian W; Zheng X
Funct Integr Genomics; 2023 May; 23(2):153. PubMed ID: 37160578
[TBL] [Abstract][Full Text] [Related]
25. Identification of anoikis-related subtypes and development of risk stratification system in skin cutaneous melanoma.
Tian J; Cao ZJ; Zhang Y; Zhou JK; Yang L
Heliyon; 2023 May; 9(5):e16153. PubMed ID: 37215879
[TBL] [Abstract][Full Text] [Related]
26. A new ferroptosis-related genetic mutation risk model predicts the prognosis of skin cutaneous melanoma.
He J; Huang W; Li X; Wang J; Nie Y; Li G; Wang X; Cao H; Chen X; Wang X
Front Genet; 2022; 13():988909. PubMed ID: 36685905
[No Abstract] [Full Text] [Related]
27. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
28. A novel pyroptosis-related LncRNA signature predicts prognosis and indicates tumor immune microenvironment in skin cutaneous melanoma.
Zhong J; Wang Z; Houssou Hounye A; Liu J; Zhang J; Qi M
Life Sci; 2022 Oct; 307():120832. PubMed ID: 35940218
[TBL] [Abstract][Full Text] [Related]
29. LSM2 is associated with a poor prognosis and promotes cell proliferation, migration, and invasion in skin cutaneous melanoma.
Sun X; Zhang J; Hu J; Han Q; Ge Z
BMC Med Genomics; 2023 Jun; 16(1):129. PubMed ID: 37312186
[TBL] [Abstract][Full Text] [Related]
30. Lower Expression of GBP2 Associated With Less Immune Cell Infiltration and Poor Prognosis in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Zhao Z; Zhang X; Xu L; Liu T; Yu S
J Immunother; 2022 Jul-Aug 01; 45(6):274-283. PubMed ID: 35543550
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
32. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
[TBL] [Abstract][Full Text] [Related]
34. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis to reveal potential therapeutic targets and prognostic biomarkers of skin cutaneous melanoma.
Zhou X; Rong R; Xiong S; Song W; Ji D; Xia X
Front Immunol; 2022; 13():914108. PubMed ID: 36032150
[TBL] [Abstract][Full Text] [Related]
36. Identification of sterile a-motif domain-containing 9-like as a potential biomarker in patients with cutaneous melanoma.
Ye J; Tang H; Xie C; Han W; Shen G; Qian Y; Xu J
PeerJ; 2023; 11():e15634. PubMed ID: 37426410
[TBL] [Abstract][Full Text] [Related]
37. Prognostic and immune-related value of STK17B in skin cutaneous melanoma.
Shi X; Zhou Q; Huang B; Xia S; Jiang Y; Fang S; Lin J
PLoS One; 2022; 17(2):e0263311. PubMed ID: 35171924
[TBL] [Abstract][Full Text] [Related]
38. Mining database for the clinical significance and prognostic value of CBX family in skin cutaneous melanoma.
Li D; Liu Y; Hao S; Chen B; Li A
J Clin Lab Anal; 2020 Dec; 34(12):e23537. PubMed ID: 32860274
[TBL] [Abstract][Full Text] [Related]
39. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract][Full Text] [Related]
40. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
